ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
25 announcements with these filters
Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.
Beta Drugs Ltd reported revenue from operations of ₹137.5 Cr (+33.0% YoY) and net profit of ₹18.55 Cr (+51.8% YoY) for Q2 FY27.
Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.
Beta Drugs Limited conducted its 21st Annual General Meeting on September 30, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and auditor ratification.
Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.
Beta Drugs Limited has scheduled its 21st Annual General Meeting for September 30, 2026, at its registered office in Baddi, Himachal Pradesh.
Beta Drugs Limited announced the re-appointment of its Statutory Auditor and an Executive Director. These re-appointments are effective from September 2026 and January 2027, respectively.
Beta Drugs Limited announced its board meeting outcome, covering AGM arrangements, auditor appointments, and the re-appointment of its Whole-Time Director, Ashutosh Shukla.
Beta Drugs Limited has scheduled a board meeting for September 3, 2026. The agenda includes fixing the 21st AGM details and approving the Director’s Report.
Beta Drugs Limited approved the allotment of 35,383 bonus equity shares. These shares were issued to holders of Compulsorily Convertible Debentures following their conversion.
Beta Drugs Limited submitted its quarterly Monitoring Agency Report for June 2026. The report tracks the utilization of Rs. 117.01 Crore raised via preferential issues.
Beta Drugs Ltd. reports Q1-FY27 revenue of INR 1,255 Mn with 21.83% EBITDA margin. Diversifying beyond core oncology into IVF via Nivian acquisition.
Beta Drugs submitted revised Limited Review Reports for the quarter ended June 2026, correcting the omission of UDINs as requested by the exchange.
Beta Drugs scheduled a board meeting for July 20, 2026. The board will review unaudited quarterly financial results for the period ended June 2026.
Beta Drugs Ltd clarified to the exchange that no undisclosed price-sensitive information caused the recent price movement. The share price change is purely market-driven.
Beta Drugs Limited completed the acquisition of a 66.09% stake in Nivian Lifesciences Private Limited. The target company became a subsidiary effective April 2026.
Beta Drugs Limited approved the allotment of 6,65,314 equity shares following debenture conversion. This routine capital action follows a 2024 agreement with institutional investors.
Beta Drugs Limited allotted 6,65,314 equity shares upon conversion of CCDs on May 25, 2026. This increases the company's paid-up share capital to ₹11.09 Crore.
Beta Drugs delivered record EBITDA but missed revenue guidance due to delayed export tenders and strategic withdrawal from the low-margin Platin segment.
Beta Drugs delivered FY26 revenue of ₹385 Cr with a shift towards high-margin branded oncology (36% of mix) and 22.57% EBITDA margin.
Beta Drugs Limited reported utilization of ₹117.01 Crore raised through preferential issues. The Monitoring Agency confirms funds were deployed for subsidiary upgradation and R&D.
Beta Drugs Ltd reported revenue from operations of ₹93.96 Cr (+0.2% YoY) and net profit of ₹9.05 Cr (+0.2% YoY) for Q4 FY26.
Beta Drugs reported consolidated annual revenue of ₹396.0 Crore, representing 7.4% growth. Net profit stood at ₹41.5 Crore as the company continues its Vision 2030 expansion.